Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Single Center Study to Evaluate the Penetration of RO7033877 Into the Lung in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RO7033877 + Bronchoscopy
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT02165293
A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval
- Conditions
- Healthy Volunteer
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 64
- Registration Number
- NCT02165332
Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 82
- Registration Number
- NCT02165345
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇲🇽Hospital Infantil de México "Federico Gomez"; Rheumatology, Mexico, Mexico
🇲🇽Hospital Universitario Dr. Jose Eleuterio Gonzalez; Pediatria, Monterrey, Mexico
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 359
- Registration Number
- NCT02165215
- Locations
- 🇺🇸
Shafran Gastroenterology Center, Winter Park, Florida, United States
🇺🇸Northwestern University-Feinberg School of Medicine; Division of Gastroenterology and Hepatology, Chicago, Illinois, United States
🇺🇸Southwest Gastroenterology, Oak Lawn, Illinois, United States
A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477
- Conditions
- Healthy Volunteer, Type 2 Diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT02164266
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 358
- Registration Number
- NCT02163759
- Locations
- 🇵🇱
EMC Instytut Medyczny S.A., Wrocław, Poland
🇵🇱AppleTreeClinics Sp. z o.o., Łódź, Poland
🇪🇪Tartu University Hospital, Tartu, Estonia
A Phase 1 Clinical Study in Healthy Volunteers to Investigate the Drug-drug Interaction Between Multiple Doses of RO7033877 and Multiple Doses of Colistin Methanesulfonate Sodium (CMS)
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT02156323
A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.
- Conditions
- Type II Diabetes Mellitus
- Interventions
- Device: Accu-Chek Smart Pix readout DeviceDevice: Accu-Chek Smart Pix Software
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 558
- Registration Number
- NCT02156349
- Locations
- 🇩🇪
Forschungsinstitut der Diabetes Akademie Mergentheim (FIDAM), Bad Mergentheim, Germany
🇩🇪Diabetes- und Gesundheitszentrum Göttingen, Gottingen, Germany
🇩🇪Diabetologicum Dresden, Dresden, Germany
An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3
- Registration Number
- NCT02151370
A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT02145026
- Locations
- 🇹🇭
Siriraj Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand
🇹🇭Thammasart Chalermprakiert Hospital, Thammasart Uni; Hematology, Pathumthani, Thailand
🇹🇭Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine, Khon Kaen, Thailand